In a report released on October 22, David Evans from Kepler Capital maintained a Buy rating on Novartis AG (NOVN – Research Report), ...

George Church-founded Dyno Therapeutics Inc. is adding to its list of pharma deals by signing a second research collaboration ...

The allergy treatment market is set to experience robust growth, with an estimated valuation of US$ 20.20 billion in 2022 and ...

Infertility Drugs MarketThe global infertility drugs market is set for significant growth over the next decade, with the ...

US private equity firm Clayton Dubilier & Rice thought it had a deal to buy Sanofi’s consumer business. Losing bidder PAI ...

The global APOL1-mediated kidney disease market is poised for substantial expansion, with projections indicating a remarkable ...

This month, the NCCN Clinical Practice Guidelines in Oncology, NCCN Guidelines, for breast cancer were updated to recommend ribociclib as a ...

The Financial Prosecutor’s Office has revoked the protection of two key witnesses in the Novartis bribery case, allowing ...

Three absurdly cheap dividend stocks that are trading at modest multiples of their expected earnings today are Merck ( MRK -0 ...

The global ulcerated necrobiosis lipoidica management market is poised for significant growth, with an anticipated valuation ...

In addition to the recent FDA approval of Kisqali for EBC patients in the US and CHMP positive opinion in Europe, regulatory ...

The NCCN has updated its breast cancer guidelines, designating Novartis' Kisqali as a Category 1 preferred CDK4/6 inhibitor ...